Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Single Rising Oral Doses of BIA 2-093 in Healthy Volunteers
NCT02171195Phase 1Completed
- Sponsor
- BIAL
- Start
- Jul 2000
- Primary completion
- Oct 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of eslicarbazepine acetate in epilepsy (8 arms), sponsored by BIAL. Primary endpoint: Total Number of Adverse Events up to 20 weeks. Started Jul 2000; status: completed.
02
Drugs
eslicarbazepine acetate
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT02171195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02171195.